Pirfenidone Inhibits Obliterative Airway Disease in Mouse Tracheal Allografts

In aggregate, these results show that the anti-fibrotic agent pirfenidone inhibits the development of the OB-like lesion in this mouse model of human chronic airway rejection, and that these effects may be mediated by TGF-β. The results also suggest that pirfenidone may be worthy of investigation in human lung transplant recipients at high risk of developing OB.